Novo Nordisk shares pop on early-stage weight loss drug trial results | masr356.com

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical large reported constructive early-stage results for its as soon as weekly amycretin weight problems drug.

The trial confirmed that the remedy, which is run by way of injection, resulted in common weight discount of twenty-two% in overweight and obese sufferers after 36 weeks. That compares with weight acquire of two.0% amongst sufferers handled with a placebo over the identical time frame.

Shares closed 7.13% increased, paring earlier positive aspects of almost 14% however nonetheless recording the perfect single session since March 2024.

Shares of fellow Danish weight problems drug maker Zealand Pharma additionally tracked increased, final up 4.7%, whereas Zepbound-maker Eli Lilly dipped in premarket commerce.

Amycretin targets the identical intestine hormone that Wegovy mimics, referred to as GLP-1, in addition to a pancreas hormone referred to as amylin that impacts starvation. Wegovy is Novo Nordisk’s flagship weight problems drug whereas Ozempic is its diabetes remedy.

The trial was carried out on 125 obese or overweight sufferers and the most typical uncomfortable side effects have been gastrointestinal, with the overwhelming majority being “gentle to reasonable in severity.”

“We’re very inspired by the subcutaneous section 1b/2a results for amycretin in individuals residing with obese or weight problems,” Martin Lange, govt vice chairman for growth at Novo Nordisk, mentioned in a press release.

“The results seen within the trial assist the weight decreasing potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that now we have beforehand seen with the oral formulation.”

Novo can be creating an amycretin weight problems tablet. Early-stage trials introduced in September, confirmed common weight loss of 13.1% after 12 weeks. The corporate mentioned on the time that the remedy was secure and tolerable for sufferers, however included gentle to reasonable uncomfortable side effects.